Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- Trial result
Multiple solid tumors
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors
Tovorafenib is an oral, selective, CNS-penetrant type II inhibitor of BRAF and CRAF evaluated as monotherapy in the Phase II FIRELIGHT-1 DAY101-102a substudy (NCT04985604) in recurrent/refractory solid tumors with…
NCT04985604 - New trial
Multiple solid tumors
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors
Recursion Pharmaceuticals’ first-in-human, open-label ZINNIA study evaluates oral REC-7735 in unresectable, locally advanced, or metastatic solid tumors with the PIK3CA H1047R mutation. The drug is designed to…
NCT07819136 First-in-human - New trial
Multiple solid tumors
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma
MD Anderson Cancer Center is running a single-center, open-label Phase 1/2 study of larotrectinib plus pembrolizumab in advanced or metastatic lung adenocarcinoma or melanoma that progressed after…
NCT07843550 Exploratory - New trial
Multiple solid tumors
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance
This Abramson Cancer Center/Penn Medicine Phase 2 study evaluates saruparib (AZD5305), AstraZeneca’s selective PARP1 inhibitor, in measurable, progressing, locally advanced or metastatic solid tumors with a positive…
NCT07832630 Exploratory - New trial
Multiple solid tumors
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings
Advenchen Pharmaceuticals’ open-label Phase 1b/2a study evaluates catequentinib hydrochloride (AL3818, also known as anlotinib), a multikinase inhibitor of angiogenesis-related signaling including VEGFR, FGFR, and…
NCT07811297 Exploratory - New trial
Multiple solid tumors
Phase 2 ADD-IT1 tests propranolol, desloratadine, nutrient repletion, and morning immunotherapy in melanoma and liver cancer
This randomized University of Southern California study evaluates a bundled adjunct strategy for patients starting first-line PD-1/PD-L1-based therapy for advanced melanoma or hepatocellular carcinoma. The…
NCT07836712 Exploratory - New trial
Multiple solid tumors
Phase 1b SX-682 CXCR1/2 chemokine-receptor inhibitor plus proton CSI for leptomeningeal metastases
Memorial Sloan Kettering Cancer Center is running a Phase 1b, open-label study testing SX-682 (a small-molecule CXCR1/CXCR2 inhibitor that blocks IL-8–axis neutrophil/MDSC trafficking and related tumor-promoting…
NCT07814352 Exploratory - New trial
Multiple solid tumors
Phase 1 AWT020 anti–PD-1–IL-2 fusion protein (checkpoint blockade + cytokine agonist)
This open-label Phase 1 study is determining the maximum tolerated dose and/or recommended Phase 2 dose of AWT020 given as intravenous monotherapy, while also characterizing safety, pharmacokinetics, immunogenicity,…
NCT07822919 Exploratory - New trial
Multiple solid tumors
Phase 1/2 PM54 oncogenic transcription inhibitor + irinotecan/doxorubicin
PharmaMar’s Phase 1/2 open-label, non-randomized master combination study tests PM54, an ecteinascidin-family transcription inhibitor that binds DNA and disrupts oncogenic transcription through RNA polymerase II…
NCT07839819 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 2 SIR2501 SARM1 inhibitor aims to prevent paclitaxel-induced peripheral neuropathy.
This Phase 2, open-label, sequential-cohort study evaluates SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy, with primary goals of characterizing safety, tolerability,…
NCT07765446 Exploratory - New trial
Multiple solid tumors
TriNav pressure-enabled infusion catheter (pressure-modulated delivery) for Y-90 resin microspheres
Stanford University’s PRESSURE trial is a prospective, randomized, within-patient study testing whether pressure-modulated intra-arterial delivery improves Y-90 resin microsphere deposition in liver metastases…
NCT07791446 Exploratory - New trial
Multiple solid tumors
Phase 2 OAT ICI tests COX inhibition + H1 antihistamine modulation alongside ICIs
This Phase 2, single-site interventional study at University of Kentucky/Markey Cancer Center evaluates whether “optimizing” common ancillary meds can improve outcomes for patients with radiographically measurable…
NCT07661459 Exploratory - New trial
Multiple solid tumors
Phase 1 GS-1206 small-molecule inhibitor tests undisclosed target in advanced solid tumors.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07703878 First-in-human - New trial
Multiple solid tumors
Phase 1 SLR-108 PTK7-targeted antibody–radionuclide conjugate for immuno-PET imaging.
This Phase 1, interventional, open-label imaging study from Solve Therapeutics is testing whether SLR-108 can feasibly visualize metastatic solid tumors on PET after a single IV administration. SLR-108 is a…
NCT07728942 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2 ARV-6723 oral PROTAC HPK1 degrader ± pembrolizumab (PD-1 mAb) in solid tumors
This first-in-human, open-label Phase 1/2 study sponsored by Arvinas evaluates ARV-6723 as monotherapy and combined with pembrolizumab (Merck/MSD’s anti–PD-1 monoclonal antibody) in adults with advanced/metastatic,…
NCT07749586 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 CS2009 PD-1/VEGFA/CTLA-4 trispecific antibody in advanced solid tumors
This first-in-human, open-label, multicenter Phase 1/2 study evaluates CS2009, CStone Pharmaceuticals’ trispecific monoclonal antibody designed to block PD-1 (reinvigorates exhausted T cells), CTLA-4 (promotes T-cell…
NCT06741644 First-in-human - Trial result Spotlight
Multiple solid tumors
Erdafitinib (pan-FGFR TKI) drives 56% ORR in FGFR-altered pancreatic cancer in RAGNAR
Erdafitinib is an oral pan-FGFR1–4 tyrosine kinase inhibitor (TKI) tested in the Phase 2, histology-agnostic RAGNAR trial (NCT04083976) in patients with advanced/unresectable/metastatic solid tumors and FGFR…
NCT04083976 - Trial result
Multiple solid tumors
CS2009 PD-1/VEGF/CTLA-4 trispecific posts 18.5% ORR in heavily pretreated NSCLC (no actionable drivers)
CS2009 is a first-in-class trispecific antibody designed to simultaneously block PD-1 and CTLA-4 immune checkpoints while neutralizing VEGF (anti-angiogenesis), evaluated in an open-label, multicenter Phase 1…
NCT06741644 - New trial
Multiple solid tumors
Phase 1/2 N17350 intratumoral ELANE-pathway therapeutic elastase (recombinant mutant elastase)
This Phase 1/2 open-label, dose-finding and expansion study (OP-NEU-101) tests intratumoral N17350 injections every 2 weeks (typically up to 12 weeks) in adults with advanced/metastatic solid tumors that have…
NCT07339176 First-in-human - New trial
Multiple solid tumors
Phase 1/2a VBC106 FRα/MSLN-targeted topo1 inhibitor antibody-drug conjugate in solid tumors.
This first-in-human, multicenter, open-label Phase 1/2a study from VelaVigo Bio evaluates VBC106, an FRα (FOLR1)- and mesothelin (MSLN)-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor…
NCT07686068 First-in-human - New trial
Multiple solid tumors
Phase 1/2 TORL-5-700 ADC; target/MOA not publicly disclosed (first-in-human)
No disclosed MOA. We do not include details of trials without this basic information.
NCT07439653 First-in-human - Trial result
Multiple solid tumors
Pembrolizumab (PD-1 blockade) + AI-derived iTIL/“tumor content” dynamics predict survival in rare-tumor basket trial
Pembrolizumab is an anti–PD-1 immune checkpoint inhibitor evaluated in a Phase II, multi-cohort rare-tumor basket study (n=84) with paired baseline (256) and on-treatment (248) biopsies analyzed on H&E using a deep…
- New trial
Multiple solid tumors
Phase 1 carfilzomib selective proteasome inhibitor via hepatic artery infusion pump for liver metastases
This National Cancer Institute (NCI) Phase 1, open-label, single-arm study tests whether carfilzomib—a selective proteasome inhibitor (approved as Kyprolis by Amgen)—can be safely delivered continuously through an…
NCT07715903 Exploratory - New trial
Multiple solid tumors
Phase 1/2a VBC108 CLDN18.2×CDH17 bispecific topo1 inhibitor ADC in advanced solid tumors.
This first-in-human, multicenter, open-label Phase 1/2a study tests VBC108, a CLDN18.2- and CDH17-directed bispecific antibody-drug conjugate from VelaVigo Bio that delivers a topoisomerase I inhibitor payload to…
NCT07700160 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b DBC-664 — Undisclosed MOA/target (first-in-human agent)
No disclosed MOA. We do not include details of trials without this basic information.
NCT07705035 First-in-human - Trial result
Multiple solid tumors
ALK201 FGFR2b ADC posts 24% ORR in refractory solid tumors with low ocular toxicity
ALK201 is a first-in-human FGFR2b-targeting antibody–drug conjugate from Allink Biotherapeutics, using a humanized anti-FGFR2b monoclonal antibody linked to the topoisomerase-I payload exatecan via a cleavable…
NCT06656390 - New trial
Multiple solid tumors
Phase 1 GS-2426 MAT2A small‑molecule inhibitor in MTAP‑deleted advanced solid tumors
This Phase 1, multicenter, open-label Gilead Sciences study evaluates GS-2426, a small-molecule inhibitor of methionine adenosyltransferase 2A (MAT2A), in adults with advanced/metastatic solid tumors harboring MTAP…
NCT07601243 Exploratory - New trial
Multiple solid tumors
Phase 1 MR-guided SBRT (adaptive MR-guided radiotherapy) single-fraction metastasis ablation
This single-arm Phase 1 study (“ONE SHOT”) evaluates feasibility, safety/tolerability, and early local control signals for single-fraction adaptive MR-guided stereotactic body radiation therapy (SBRT) in patients…
NCT07671768 Exploratory - New trial
Multiple solid tumors
Phase 2 gemcitabine + mitomycin C cytotoxics with thalidomide anti-angiogenic immunomodulator
This open-label, single-arm Phase 2 study sponsored by Sarcoma Oncology Research Center, LLC evaluates a “metronomic” (frequent, lower-dose) combination intended to balance disease control with tolerability in…
NCT07671534 Exploratory - Trial result Spotlight
Multiple solid tumors
Olverembatinib (HQP1351) hits p38–CD36 lipid-scavenging axis, delivers 23% PR and 25.7-mo PFS in SDH-deficient GIST
Olverembatinib (HQP1351) is an oral multikinase TKI with p38 inhibition implicated here in downregulating CD36 (fatty-acid uptake), a metabolic vulnerability in SDH-deficient tumors. In the HQP1351SJ0003 Phase 1b…
NCT03594422
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.